½ÃÀ庸°í¼­
»óǰÄÚµå
1494320

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - µµÀÔº°, °Ë»ç À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°

Asia Pacific ELISA Diagnostics Tests Market Forecast to 2030 - Regional Analysis - by Adoption, Test Type, Application, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 111 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀåÀº 2022³â 2¾ï 5,570¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2030³â¿¡´Â 5¾ï 308¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2022-2030³â µ¿¾È 8.8%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Çõ½ÅÀûÀÎ Á¦Ç° Ãâ½Ã·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå °­È­

ELISA °Ë»ç´Â À¯¿¬¼º, ¹Î°¨µµ, »ç¿ë ÆíÀǼº µî ´Ù¾çÇÑ ÀåÁ¡À¸·Î ÀÎÇØ °¡Àå ³Î¸® »ç¿ëµÇ´Â ¸é¿ª ÃøÁ¤ °Ë»ç Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ ELISA °Ë»ç ŰƮÀÇ Àú·ÅÇÑ °¡°Ý°ú °í¼º´É °Ë»ç¿¡ µû¸¥ ´Ù¸éÀû Àû¿ë¼ºÀ¸·Î ÀÎÇØ ´Ù¾çÇÑ ¿¬±¸ ¹× IVD ¿ä±¸ »çÇ׿¡ ÀÌ»óÀûÀÎ ¼Ö·ç¼ÇÀ̵Ǿú½À´Ï´Ù. Àúºñ¿ëÀÇ Àû¿ë °¡´É¼ºÀ¸·Î ÀÎÇØ °Ë»ç ŰƮÀÇ Á¦Ç° Çõ½ÅÀº Àΰ£ ¹× µ¿¹° ¿¬±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¦Á¶¾÷üµéÀº ÀÚü ½Ã¼³À» °®Ãá ELISA °Ë»ç ŰƮ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, Innovative Research´Â ÀÀ°íÀÎÀÚ, »ý¹°Á¾ ¹× Ç×ü¸¦ ½Äº°Çϱâ À§ÇØ ±¤¹üÀ§ÇÑ ¼±ÅüºÀ» °¡Áø ELISA ŰƮ¸¦ ÆÇ¸ÅÇϰí ÀÖ½À´Ï´Ù. 'Àΰ£ Ç÷¾×ÀÀ°íÀÎÀÚ IX ŰƮ'µµ ±× Áß ÇϳªÀÔ´Ï´Ù. Àΰ£ Ç÷¾×ÀÀ°íÀÎÀÚ IX Ç׿ø ºÐ¼®Àº Àΰ£ Ç÷Àå ³» Àüü IX ÀÎÀÚ Ç׿øÀ» Á¤·®ÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÕ´Ï´Ù. ÀÌ Å°Æ®´Â ¿¬±¸ ¸ñÀûÀ¸·Î¸¸ »ç¿ëÇϵµ·Ï ±ÇÀåµÇ¸ç, ½Ã¾àÀº ÃÖ´ë 96°³ÀÇ ÀÓ»ó °Ë»ç¿¡ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, COVID-19°¡ À¯ÇàÇÏ´Â µ¿¾È °¢ Á¦Á¶¾÷üµéÀÌ Çõ½ÅÀûÀÎ ELISA °Ë»ç Á¦Ç°À» Ãâ½ÃÇϸ鼭 Àΰ£¿¡ ´ëÇÑ ELISA °Ë»çÀÇ º¸±ÞÀÌ °¡¼ÓÈ­µÇ°í ÀÖÀ¸¸ç, 2022³â 12¿ù Pictor Limited´Â 'PictArray SARS-CoV-2 Ç×ü °Ë»ç' ½ÅÁ¦Ç°À» ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. ÀÌ ½ÅÁ¦Ç°Àº COVID-19 ¹ÙÀÌ·¯½º¿Í °ü·ÃµÈ °¨¿°À» °¨ÁöÇϰí, ¾òÀº ÀÓ»ó °á°ú´Â ȯÀÚ¿Í Àǻ簡 SARS-CoV-2 °¨¿°À» Ä¡·áÇÏ°í °ü¸®ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üÀÇ Çõ½ÅÀûÀÎ ELISA °Ë»ç ŰƮ Ãâ½Ã´Â Àú·ÅÇÑ ºñ¿ëÀ¸·Î ´Ù°¢ÀûÀÎ Àû¿ëÀÌ °¡´ÉÇϸç, ´Ù¾çÇÑ »ý¹°Á¾°ú °ü·ÃµÈ ´Ù¾çÇÑ °¨¿°¼º ÁúȯÀÇ Áø´Ü¿¡ È¿°úÀûÀÎ ÀÓ»ó °á°ú¸¦ Á¦°øÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù. µû¶ó¼­ Çõ½ÅÀûÀÎ Á¦Ç°ÀÇ Ãâ½Ã´Â Àå±âÀûÀ¸·Î Á¦Á¶¾÷ü¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ELISA Áø´Ü °Ë»ç ½ÃÀå °³¿ä

Áß±¹Àº Àü¿°º´ÀÇ À§ÇùÀÌ È®»êµÇ±â Àü¿¡ ½Å¼ÓÇÏ°Ô ¿¹¹æ, ŽÁö ¹× ´ëÀÀÇÒ ¼ö ÀÖ´Â °­·ÂÇϰí ź·ÂÀûÀÎ °øÁߺ¸°Ç ½Ã½ºÅÛÀ» º¸À¯Çϰí ÀÖ½À´Ï´Ù. 2023³â 9¿ù Journal of Global Health¿¡ °ÔÀçµÈ ³í¹®Àº Áß±¹ ³²µ¿ºÎ Àå¾¥¼º(Jiangsu Province)ÀÇ ¿¬°£ ½Å°í °¡´ÉÇÑ Àü¿°º´ ¹ß»ý·ü°ú Ä¡»çÀ²¿¡ ´ëÇÑ ¿¬±¸ °á°ú¸¦ ¹ßÇ¥Çß½À´Ï´Ù. Áß±¹ ³²µ¿ºÎ Àå¾¥¼º¿¡¼­ ½Å°í °¡´ÉÇÑ °¨¿°º´ÀÇ ¿¬°£ ¹ß»ý·ü°ú Ä¡»çÀ²¿¡ ´ëÇÑ ¿¬±¸°¡ ÁøÇàµÇ¾ú½À´Ï´Ù. ÀÌ ¿¬±¸´Â °øÁß º¸°Ç Á¤Ã¥ÀÌ Á¶»ç ±â°£ µ¿¾È Àå³», ¸Å°³ ¹× Àμö°øÅë°¨¿°º´ ¹ß»ý·ü°ú ±×¿¡ µû¸¥ Ä¡»çÀ²À» °¨¼Ò½ÃŰ´Â µ¥ È¿°úÀûÀ̾úÁö¸¸ ¸Åµ¶°ú ¿¡ÀÌÁ Áß½ÉÀ¸·Î ÇÑ ¼ºº´°ú Ç÷¾× ¸Å°³ °¨¿°ÀÇ ¹ß»ý·üÀº Áõ°¡Çß´Ù°í °á·ÐÁö¾ú½À´Ï´Ù.

¶ÇÇÑ, ¼¼°è °¢Áö·Î »¸¾î³ª°¡´Â Ç×°ø ³ë¼±¸ÁÀÇ È®´ë·Î ÀÎÇØ COVID-19¿Í °°Àº Àü¿°º´ÀÇ ±Þ¼ÓÇÑ È®»ê À§ÇèÀÌ ±Þ°ÝÈ÷ Áõ°¡ÇÏ¿© ¼¼°è ¹«¿ªÀÇ Áß´Ü, ¹ßº´ÀÚ Áõ°¡, »ç¸ÁÀÚ Áõ°¡¸¦ ÃÊ·¡ÇÏ´Â ´ëÀ¯ÇàÀ¸·Î À̾îÁú ¼ö ÀÖ´Â Àü¿°º´ÀÇ È®»ê À§ÇèÀÌ ±Þ°ÝÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ ³ª¶ó´Â Áß±¹ ³» ELISA Áø´Ü °Ë»ç ½ÃÀå¿¡ Âü¿©ÇÏ´Â ±¹³»¿Ü ±â¾÷µé¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç ELISA Áø´Ü °Ë»ç ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

¾Æ½Ã¾ÆÅÂÆò¾ç ELISA Áø´Ü °Ë»ç ½ÃÀå ¼¼ºÐÈ­

¾Æ½Ã¾ÆÅÂÆò¾ç ELISA Áø´Ü °Ë»ç ½ÃÀåÀº µµÀÔ, °Ë»ç À¯Çüº°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× ±¹°¡¸¦ ±âÁØÀ¸·Î ¼¼ºÐÈ­µË´Ï´Ù. µµÀÔ¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀåÀº Àΰ£°ú µ¿¹°·Î ¾çºÐµÇ¸ç, 2022³â ½ÃÀå Á¡À¯À²Àº Àΰ£ÀÌ ´õ Å®´Ï´Ù.

°Ë»ç À¯Çüº°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç ELISA Áø´Ü °Ë»ç ½ÃÀåÀº »÷µåÀ§Ä¡ ELISA, °£Á¢ ELISA, °æÀï ELISA, ´ÙÁß ¹× ÈÞ´ë¿ë ELISA·Î ±¸ºÐµË´Ï´Ù. °£Á¢ ELISA ºÎ¹®ÀÌ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¿ëµµº°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç ELISA Áø´Ü °Ë»ç ½ÃÀåÀº ÀÚ°¡¸é¿ªÁúȯ, °¨¿°¼º Áúȯ, ¾Ï Áø´Ü, ´Ü¹éÁú Á¤·®, ±âŸ·Î ºÐ·ùµË´Ï´Ù. °¨¿°¼º Áúȯ ºÎ¹®ÀÌ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î ¾Æ½Ã¾ÆÅÂÆò¾ç ELISA Áø´Ü °Ë»ç ½ÃÀåÀº º´¿ø ¹× Áø´Ü ¼¾ÅÍ, Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷, µ¿¹°º´¿ø ¹× Áø´Ü ¿¬±¸¼Ò, ±âŸ·Î ºÐ·ùµË´Ï´Ù. º´¿ø ¹× Áø´Ü ¼¾ÅÍ ºÎ¹®ÀÌ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾ç ELISA Áø´Ü °Ë»ç ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµÇ¸ç, 2022³â ¾Æ½Ã¾ÆÅÂÆò¾ç ELISA Áø´Ü °Ë»ç ½ÃÀå Á¡À¯À²Àº Áß±¹ÀÌ µ¶Â÷ÁöÇß½À´Ï´Ù.

Bio-Rad Laboratories Inc., Indexx Laboratories Inc., F. Hoffmann-La Roche Ltd. Ltd., Pictor Ltd., DiaSorin SpA, Elabscience Biotechnology Inc., Bio-Techne Corp. µîÀÌ ¾Æ½Ã¾ÆÅÂÆò¾ç ELISA Áø´Ü °Ë»ç ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷µéÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå : ÁÖ¿ä »ê¾÷ ¿ªÇÐ

  • ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • µ¿¹°ÀÇ °¨¿°Áõ Áõ°¡
    • Àΰ£ °¨¿°Áõ ¹ß»ý·ü Áõ°¡
  • ÁÖ¿ä ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Á¦Ç° ȸ¼ö ¹ß»ý
  • ÁÖ¿ä ½ÃÀå ±âȸ
    • Çõ½ÅÀûÀÎ Á¦Ç° Ãâ½Ã
  • ÇâÈÄ µ¿Çâ
    • ELISA ±â¹Ý ÀýÂ÷ÀÇ Áøº¸

Á¦5Àå ELISA Áø´Ü °Ë»ç ½ÃÀå : ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®

  • ¼Ò°³
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå ¸ÅÃâ, 2022-2030³â

Á¦6Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå : ¸ÅÃâ°ú 2030³â±îÁö ¿¹Ãø : µµÀÔº°

  • ¼Ò°³
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå : 2022³â¡¤2030³â µµÀÔº° ¸ÅÃâ Á¡À¯À²(%)
  • Àΰ£
  • µ¿¹°

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå : ¸ÅÃâ°ú 2030³â±îÁö ¿¹Ãø : °Ë»ç À¯Çüº°

  • ¼Ò°³
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå : 2022³â¡¤2030³â °Ë»ç À¯Çüº° ¸ÅÃâ Á¡À¯À²(%)
  • »÷µåÀ§Ä¡ ELISA
  • °£Á¢ ELISA
  • °æÀï ELISA
  • ¸ÖƼÇà ¹× ÈÞ´ë¿ë ELISA

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå : ¿ëµµº° ¸ÅÃâ°ú 2030³â±îÁö ¿¹Ãø

  • ¼Ò°³
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå : 2022³â¡¤2030³â ¿ëµµº° ¸ÅÃâ Á¡À¯À²(%)
  • ÀÚ°¡¸é¿ªÁúȯ
  • °¨¿°Áõ
  • ¾Ï Áø´Ü
  • ´Ü¹éÁú Á¤·®
  • ±âŸ

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ¸ÅÃâ°ú 2030³â±îÁö ¿¹Ãø

  • ¼Ò°³
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå : 2022³â¡¤2030³â ÃÖÁ¾»ç¿ëÀÚº° ¸ÅÃâ Á¡À¯À²(%)
  • º´¿ø¡¤Áø´Ü ¼¾ÅÍ
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • µ¿¹° º´¿ø¡¤Áø´Ü ½ÇÇè½Ç
  • ±âŸ

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ELISA Áø´Ü °Ë»ç ½ÃÀå : 2030³â±îÁö ¸ÅÃâ°ú ¿¹Ãø : ±¹°¡º° ºÐ¼®

  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦11Àå ELISA Áø´Ü °Ë»ç ½ÃÀå - ¾÷°è »óȲ

  • ¼Ò°³
  • ELISA Áø´Ü °Ë»ç ½ÃÀå ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«

Á¦12Àå ±â¾÷ °³¿ä

  • Bio-Rad Laboratories Inc
  • Idexx Laboratories Inc
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc
  • Abbott Laboratories
  • Danaher Corp
  • Pictor Ltd
  • DiaSorin SpA
  • Elabscience Biotechnology Inc
  • Bio-Techne Corp

Á¦13Àå ºÎ·Ï

ksm 24.06.20

The Asia Pacific ELISA diagnostics tests market was valued at US$ 255.70 million in 2022 and is expected to reach US$ 503.08 million by 2030; it is estimated to grow at a CAGR of 8.8% from 2022 to 2030.

Innovative Product Launches Bolster Asia Pacific ELISA Diagnostics Tests Market

ELISA is one of the most popular immunoassay tests owing to its various advantages such as flexibility, sensitivity, and easy-to-use features. Also, low cost of ELISA test kit and multifaceted applicability associated with high-throughput testing make it an ideal solution for various research and IVD requirements. With low-cost applicability, product innovations in the test kits enhance the demand for human and animal research. Also, manufacturers focus on developing ELISA test kits with in-house facilities. Innovative Research company sells a wide range of ELISA kits with selectivity to a broad range in identifying coagulants, species, and antibodies. "Human Factor IX Kit" is one such example manufactured by Innovative Research. The human coagulation Factor IX antigen assay is intended for the quantitative determination of total Factor IX antigen in human plasma. The kit is recommended to use only for research purposes, and reagents can be utilized for up to 96 clinical tests. Additionally, innovative product launches for ELISA tests by the manufacturers amid the COVID-19 pandemic accelerate the adoption of ELISA testing among humans. In December 2022, Pictor Limited announced a new product launch of the "PictArray SARS-CoV-2 Antibody Test," which has demonstrated real clinical utility intended for patients and doctors. The new product detects the infection associated with the COVID-19 virus, and the clinical results produced assist the patients and doctors in treating and managing SARS-CoV-2 infection. Launches of innovative ELISA test kits by manufacturers are expected to provide effective clinical results for diagnosing varied infections associated with different types of species with low cost and multifaceted applications. Thus, innovative product launches would provide lucrative opportunities for manufacturers in the long run.

Asia Pacific ELISA Diagnostics Tests Market Overview

China has a strong and resilient public health system that can rapidly prevent, detect, and respond to infectious disease threats before they become epidemics. China's ecology poses a risk for emerging, re-emerging, and novel diseases that could threaten China and the Rest of world owing to the vast population of ~ 1.4 billion and 50% of the world's livestock. In an article published by Journal of Global Health in September 2023, a study was carried out on annual incidence and fatality rates of notifiable infectious diseases in Jiangsu province of southeast China. The study concluded that public health policies have been effective in reducing the incidence of intestinal, vector-borne, and zoonotic diseases during the study period and the associated fatality, but that the incidence of sexually transmitted and blood-borne diseases, mainly syphilis and AIDS, has increased.

Additionally, growing network of air travel routes across the world dramatically increases the risk of rapid infection spread, including infections that may lead to pandemics, such as the COVID-19 pandemic, that result in disruption of global trade, rise in illness cases, or increase in deaths. The country is expected to provide lucrative opportunities to local and international players involved in ELISA diagnostics test market in the country.

Asia Pacific ELISA Diagnostics Tests Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific ELISA Diagnostics Tests Market Segmentation

The Asia Pacific ELISA diagnostics tests market is segmented based on adoption, test type, application, end user, and country. Based on adoption, the Asia Pacific ELISA diagnostics tests market is bifurcated into human and veterinary. The human segment held a larger market share in 2022.

In terms of test type, the Asia Pacific ELISA diagnostics tests market is segmented into sandwich ELISA, indirect ELISA, competitive ELISA, and multiple & portable ELISA. The indirect ELISA segment held the largest market share in 2022.

Based on application, the Asia Pacific ELISA diagnostics tests market is segmented into autoimmune diseases, infectious diseases, cancer diagnosis, protein quantification, and others. The infectious diseases segment held the largest market share in 2022.

By end user, the Asia Pacific ELISA diagnostics tests market is segmented into hospitals & diagnostic centers, pharmaceutical & biotechnology companies, veterinary hospitals & diagnostic laboratories, and others. The hospitals & diagnostic centers segment held the largest market share in 2022.

Based on country, the Asia Pacific ELISA diagnostics tests market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific ELISA diagnostics tests market share in 2022.

Bio-Rad Laboratories Inc., Idexx Laboratories Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corp., Pictor Ltd., DiaSorin SpA, Elabscience Biotechnology Inc., and Bio-Techne Corp are some of the leading companies operating in the Asia Pacific ELISA diagnostics tests market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation
    • 1.2.1 Asia Pacific ELISA Diagnostic Tests Market - by Adoption
    • 1.2.2 Asia Pacific ELISA Diagnostic Tests Market - by Test Type
    • 1.2.3 Asia Pacific ELISA Diagnostic Tests Market - by Application
    • 1.2.4 Asia Pacific ELISA Diagnostic Tests Market - by End User
    • 1.2.5 Asia Pacific ELISA Diagnostic Tests Market - by Country

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific ELISA Diagnostic Test Market - Key Industry Dynamics

  • 4.1 Key Market Drivers
    • 4.1.1 Rising Infectious Diseases Among Animals
    • 4.1.2 Increasing Incidence of Human Infections
  • 4.2 Key Market Restraints
    • 4.2.1 Incidents of Product Recalls
  • 4.3 Key Market Opportunities
    • 4.3.1 Innovative Product Launches
  • 4.4 Future Trends
    • 4.4.1 Advancements in ELISA-Based Procedures

5. ELISA Diagnostic Tests Market - Asia Pacific Market Analysis

  • 5.1 Overview
  • 5.2 Asia Pacific ELISA Diagnostic Tests Market Revenue (US$ Mn), 2022 - 2030

6. Asia Pacific ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 - by Adoption

  • 6.1 Overview
  • 6.2 Asia Pacific ELISA Diagnostic Tests Market Revenue Share, by Adoption 2022 & 2030 (%)
  • 6.3 Human
    • 6.3.1 Overview
    • 6.3.2 Human: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Veterinary
    • 6.4.1 Overview
    • 6.4.2 Veterinary: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 - by Test Type

  • 7.1 Overview
  • 7.2 Asia Pacific ELISA Diagnostic Tests Market Revenue Share, by Test Type 2022 & 2030 (%)
  • 7.3 Sandwich ELISA
    • 7.3.1 Overview
    • 7.3.2 Sandwich ELISA: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Indirect ELISA
    • 7.4.1 Overview
    • 7.4.2 Indirect ELISA: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Competitive ELISA
    • 7.5.1 Overview
    • 7.5.2 Competitive ELISA: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Multiple & Portable ELISA
    • 7.6.1 Overview
    • 7.6.2 Multiple & Portable ELISA: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 - by Application

  • 8.1 Overview
  • 8.2 ELISA Diagnostic Tests Market Revenue Share, by Application 2022 & 2030 (%)
  • 8.3 Autoimmune Diseases
    • 8.3.1 Overview
    • 8.3.2 Autoimmune Diseases: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Infectious Disease
    • 8.4.1 Overview
    • 8.4.2 Infectious Disease: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Cancer Diagnosis
    • 8.5.1 Overview
    • 8.5.2 Cancer Diagnosis: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Protein Quantification
    • 8.6.1 Overview
    • 8.6.2 Protein Quantification: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 Asia Pacific ELISA Diagnostic Tests Market Revenue Share, by End User 2022 & 2030 (%)
  • 9.3 Hospitals & Diagnostic Centers
    • 9.3.1 Overview
    • 9.3.2 Hospitals & Diagnostic Centers: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Pharmaceutical & Biotechnology Companies
    • 9.4.1 Overview
    • 9.4.2 Pharmaceutical & Biotechnology Companies: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Veterinary Hospitals & Diagnostic Laboratories
    • 9.5.1 Overview
    • 9.5.2 Veterinary Hospitals & Diagnostic Laboratories: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 - Country Analysis

  • 10.1 Asia Pacific: ELISA Diagnostic Tests Market
    • 10.1.1 Asia Pacific: ELISA Diagnostic Tests Market, by Country
      • 10.1.1.1 China: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.1.1 Overview
        • 10.1.1.1.2 China: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.1.3 China: ELISA Diagnostic Tests Market, by Adoption, 2020-2030 (US$ Million)
        • 10.1.1.1.4 China: ELISA Diagnostic Tests Market, by Test Type, 2020-2030 (US$ Million)
        • 10.1.1.1.5 China: ELISA Diagnostic Tests Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.1.6 China: ELISA Diagnostic Tests Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.2 Japan: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 Japan: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.3 Japan: ELISA Diagnostic Tests Market, by Adoption, 2020-2030 (US$ Million)
        • 10.1.1.2.4 Japan: ELISA Diagnostic Tests Market, by Test Type, 2020-2030 (US$ Million)
        • 10.1.1.2.5 Japan: ELISA Diagnostic Tests Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.2.6 Japan: ELISA Diagnostic Tests Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.3 India: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 India: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.3 India: ELISA Diagnostic Tests Market, by Adoption, 2020-2030 (US$ Million)
        • 10.1.1.3.4 India: ELISA Diagnostic Tests Market, by Test Type, 2020-2030 (US$ Million)
        • 10.1.1.3.5 India: ELISA Diagnostic Tests Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.3.6 India: ELISA Diagnostic Tests Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.4 Australia: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
        • 10.1.1.4.2 Australia: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.3 Australia: ELISA Diagnostic Tests Market, by Adoption, 2020-2030 (US$ Million)
        • 10.1.1.4.4 Australia: ELISA Diagnostic Tests Market, by Test Type , 2020-2030 (US$ Million)
        • 10.1.1.4.5 Australia: ELISA Diagnostic Tests Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.4.6 Australia: ELISA Diagnostic Tests Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.5 South Korea: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 Overview
        • 10.1.1.5.2 South Korea: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.3 South Korea: ELISA Diagnostic Tests Market, by Adoption, 2020-2030 (US$ Million)
        • 10.1.1.5.4 South Korea: ELISA Diagnostic Tests Market, by Test Type, 2020-2030 (US$ Million)
        • 10.1.1.5.5 South Korea: ELISA Diagnostic Tests Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.5.6 South Korea: ELISA Diagnostic Tests Market, by End User, 2020-2030 (US$ Million)
      • 10.1.1.6 Rest of Asia Pacific: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
        • 10.1.1.6.2 Rest of Asia Pacific: ELISA Diagnostic Tests Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.3 Rest of Asia Pacific: ELISA Diagnostic Tests Market, by Adoption, 2020-2030 (US$ Million)
        • 10.1.1.6.4 Rest of Asia Pacific: ELISA Diagnostic Tests Market, by Test Type, 2020-2030 (US$ Million)
        • 10.1.1.6.5 Rest of Asia Pacific: ELISA Diagnostic Tests Market, by Application, 2020-2030 (US$ Million)
        • 10.1.1.6.6 Rest of Asia Pacific: ELISA Diagnostic Tests Market, by End User, 2020-2030 (US$ Million)

11. ELISA Diagnostics Test Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in ELISA diagnostics test Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Bio-Rad Laboratories Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Idexx Laboratories Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 F. Hoffmann-La Roche Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Thermo Fisher Scientific Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Abbott Laboratories
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Danaher Corp
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Pictor Ltd
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 DiaSorin SpA
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Elabscience Biotechnology Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Financial Overview
    • 12.9.4 SWOT Analysis
    • 12.9.5 Key Developments
  • 12.10 Bio-Techne Corp
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦